A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer

OBJECTIVES: Neoadjuvant therapy followed by radical resection improves the borderline-resectable pancreatic cancer (BRPC) prognosis; however, the optimal therapeutic regimen remains unclear. Gemcitabine plus nab-paclitaxel (GnP) showed a high anti-tumor effect in primary lesions in a prospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Okano, Naohiro, Matsuki, Ryota, Toki, Masao, Gondo, Koichi, Ochiai, Kazushige, Watanabe, Shunsuke, Tateishi, Hidekatsu, Kogure, Masaharu, Suzuki, Yutaka, Sugiyama, Masanori, Nagashima, Fumio, Shibahara, Junji, Sakamoto, Yoshihiro, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970803/
https://www.ncbi.nlm.nih.gov/pubmed/35793961
http://dx.doi.org/10.2169/internalmedicine.9504-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970803/
https://www.ncbi.nlm.nih.gov/pubmed/35793961
http://dx.doi.org/10.2169/internalmedicine.9504-22

Ejemplares similares